Sign in
Taking people in United StatesPhase 2

A Trial of Varenicline for E-cigarette Cessation

Key facts

Who runs it
Yale University
Where
Charleston and New Haven, United StatesSee the 2 sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
326 people, planned
Started
14 Oct 2025
Expected to end
30 Oct 2030
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Varenicline 1mg BID
  • Placebo
Record updated
17 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (6)Hide the full registry criteria

Who can take part

  • report daily use of an e-cigarette containing nicotine
  • live in Connecticut or South Carolina

Who cannot take part

  • regular use of other tobacco products besides e-cigarettes
  • medical contraindications for varenicline use
  • current treatment for tobacco cessation
  • lack proficiency in English

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • E-cigarette use or vaping or nicotine dependence

This trial is currently available in United States.

  • Hollings Cancer Center at MUSC (HCC)Charleston, United StatesContact: Lisa Fucito, PhDTaking people
  • Yale Cancer Center, Smilow Cancer Hospital at Yale New HavenNew Haven, United StatesContact: Lisa Fucito, PhDTaking people

About the trial

What the trial wants to find out

This is randomized, placebo-controlled clinical trial in treatment-seeking adults who report regular e-cigarette use to test the hypothesis that varenicline is efficacious for quitting e-cigarettes.

The 2 groups in the trial

  • VareniclineTreatment being tested

    Participants will randomly be assigned to 12-weeks of varenicline (titrated to 2mg daily) plus brief cessation advice with a counselor and self-management resources.

    Treatment: Varenicline 1mg BID

  • PlaceboPlacebo, for comparison

    Participants will randomly be assigned to 12-weeks of matching placebo plus brief cessation advice with a counselor and self-management resources.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Investigating Efficacious E-Cigarette Interventions and Cessation Effects on Cancer-Related Biomarkers: A Randomized Trial of Varenicline in Adults
Criteria questions
Built from NCT07040566, who can take part
Record updated
17 December 2025